Point of Care (POC) Diagnostics Market Analysis, Size, Share, Growth and Forecast to 2020 | Hexa Research

The Global Point of Care Diagnostics Market is driven by technological improvements and introduction of sophisticated medical solutions. A host of healthcare establishments are gradually taking to point of care tests and diagnostics solutions for greater efficiency. Growing popularity of EMR (electronic medical record) and PACS (picture archiving and communication systems) has a positive impact on market demand.

Other industry drivers are governmental support, surging healthcare investments, growing geriatric population, and widespread adoption of home based POC devices. When medical diagnostics tests are carried out at the place of patient care, it is known as bedside testing or POCT (point-of-care-testing). New product development is a vital factor that may contribute significantly to market growth during the forecast period (2012 to 2020).

Browse Details of Report@

https://www.hexaresearch.com/research-report/point-of-care-diagnostics-industry

Products, end users, and regions are the parameters based on which the global point of care (POC) diagnostics industry is categorized. As per products, the segments are blood gas/electrolytes, fertility, cardiac markers, OTC & rapid diagnostic tests, infectious diseases, coagulation, drug abuse testing, hospital glucose testing, decentralized clinical chemistry, hematology, and urinalysis. Products also include primary care systems, such as HbA1c tests and lipid profiling. Hospital glucose testing holds the highest market share. Factors that propel this segment are high incidence of diabetes and the growing necessity for glucose analysis on a regular basis.

The OTC & rapid diagnostic tests market may expand robustly over the forecast period because of the “self diagnosis” trend. People nowadays are highly aware of the importance of early disease diagnosis for on-time & instant disease treatment. Based on end users, the global industry is divided into laboratories, hospitals, clinics, assisted living healthcare facilities, homes, and others. Hospitals & clinics generate highest revenues in the overall market. Diagnostic tests are mostly conducted in clinics and in hospitals. As a result, most of these healthcare centers have begun expanding their POC diagnostic facilities.

Geographically, the worldwide Point Of Care Diagnostics Market is categorized into Asia Pacific, Europe, North America, and Rest of the World (RoW). North America is the largest regional industry. High degree of patient awareness, encouraging government initiatives, and substantial investments in medical infrastructure are prominent regional drivers. It is however, expected that Asia Pacific will register the highest growth rate over the forecast period. This attributes to improvements in healthcare infrastructure in emerging countries, such as India and China.

Companies operating in the global Point Of Care Diagnostics Market continuously strive towards capturing higher market shares. They invest robustly in R&D and product innovations. Prominent market competitors are Trinity Biotech PLC, Danaher Corporation, Siemens Healthcare, Roche Diagnostics, and Becton Dickinson and Company.

In September 2016, Novartis launched the NijiTM System and Total IgE Test, a POC diagnostic tool. By using just a droplet or two of finer stick blood, this device delivers Immunoglobulin E (IgE) levels in a matter of twelve minutes. This test caters to immediate in-office diagnosis of allergies associated with IgE levels. The availability of such tests in the offices of healthcare providers leads to reduced time for consultation, diagnosis, prognosis, and disease treatment. This in turn leads to better patient outcomes.

Browse Related Category Market Reports @

https://www.hexaresearch.com/research-category/clinical-diagnostics-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com/

Visit Our Blog - hexaresearch1.blogspot.com

Peptide Therapeutics Market Analysis, Size, Share, Growth and Forecast to 2020 | Hexa Research

Rising cases of cancer and high incidence of a number of metabolic diseases propel the global peptide therapeutics market. Other industry drivers are prevalence of lifestyle diseases, introduction of hybrid methods of peptides synthesis, growing global population, and improved healthcare infrastructure. A molecule containing two or more amino acids is known as a peptide. Therapeutic peptides are short amino acid monomer chains.

Peptides are commonly known as amide bonds. These are used to treat blood-based disorders, certain types of cancers, chronic ailments, CNS (central nervous system) disorders, and cardiovascular & respiratory anomalies. Growing importance of peptide therapeutics in the pharmaceutical market may significantly contribute to overall demand during the forecast period (2012 to 2020). However, changing customer needs and lack of regulatory standards hinder industry progress.

Browse Details of Report@https://www.hexaresearch.com/research-report/peptide-therapeutics-industry

The worldwide peptide therapeutics market is categorized on the basis of technologies, applications, routes of administration, products, and regions. Based on technologies, the segments are HPPS (hybrid phase peptide synthesis), LPPS (liquid phase peptide synthesis), and SPPS (solid phase peptide synthesis). Owing to cost effectiveness and user-friendliness, SPPS was the largest contributor to the overall industry in 2013.On the basis of applications, the market is divided into respiratory, cancer, anti-infection, pain, metabolic, cardiovascular, dermatology, renal, gastro intestinal, and others. In 2013, peptide therapeutics were used extensively in cancer treatment. High incidence of cancer cases worldwide is expected to fuel this segment till 2020.

According to routes of administration, the industry is segmented into mucosal, pulmonary, parenteral, oral, and others. “Others” includes nasal and intradermal. Parenteral held the highest industry share in 2013. Based on products, the bifurcations are generic and innovative. Innovative peptides dominated the overall industry in 2013.

As per regions, the global peptide therapeutics market is categorized into Europe, Asia Pacific, North America, and Rest of the World. North America leads the global industry because of high per capita expenditure on healthcare, rising income levels, and improvements in healthcare infrastructure. The region receives substantial support from the government and also from a number of NGOs.

Asia Pacific may witness robust growth over the forecast period because of economic progress, favorable government initiatives, and growing population. Japan, China, and India are the three key regional drivers of the Asia Pacific market. Prominent companies operating in the global peptide therapeutics market are Eli Lilly and Company; Takeda Pharmaceutical Company Ltd.; Amylin Pharmaceuticals LLC; Bachem Holding AG; and Teva Pharmaceuticals.

Rhythm, a U.S. based biopharmaceutical company dealing in peptide therapeutics presented the phase 2 clinical trial assessment of setmelanotide in November 2016. Setmelanotide, a peptide drug, is the company’s melanocortin-4 receptor agonist that is generally used to treat LepR (leptin receptor) deficiency obesity. This is a rare genetic anomaly that leads to unrelenting hyperphagia and severe obesity. According to the company, this disorder affects nearly two thousand people in the U.S. on an annual basis.

Caused by deficiencies & defects in the MC4 pathway, LepR deficiency obesity affects people in their early childhood. The MC4 pathway in humans regulates appetite, energy expenditure, and homeostasis. Setmelanotide’s efficacy was tested by researchers when it was administered everyday by subcutaneous injection. Over a period of 22 weeks, a LepR patient lost weight by almost 20%.

Browse Related Category Market Reports @

https://www.hexaresearch.com/research-category/healthcare-it-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com/

Visit Our Blog - hexaresearch1.blogspot.com

Allergy Diagnostics And Therapeutics Market Size, Share, Growth and Forecast to 2022 | Hexa Research

The Global Allergy Diagnostics And Therapeutics Market is anticipated to grow at a CAGR exceeding 12% during the forecast period (2016 to 2022). This attributes to the problem of environmental pollution and high incidence of allergic diseases. The probability of children below 14 years of age being afflicted with chronic allergies is a prominent factor that fuels industry demand. Frequent need for in-vitro blood tests may drive this market over the forecast period. Widespread adoption of diagnostics for treating inhaled allergies caused by air pollution could significantly contribute to demand. Nowadays, people are highly susceptible to allergies because of changing lifestyles, unhealthy dietary patterns, and urbanization.

The worldwide allergy diagnostics and therapeutics market is categorized on the basis of products, type of allergens, end uses, tests, drug classes, and geographies. On the basis of products, the segments are services, consumables, and instruments. Immunoassay analyzers, luminometers, and other diagnostic devices are few of the commonly used equipment. Popularity of immunoassay analyzers is by far the highest in most developing economies of the world.

Browse Details of Report@

https://www.hexaresearch.com/research-report/allergy-diagnostic-market

Various types of allergens are drug allergens, inhaled allergens, food allergens, and others. Inhaled allergens held the highest industry share over the past couple of years because of numerous cases of air pollution based allergies.

Based on end uses, the industry is trifurcated into diagnostics laboratories, and academic research institutes. Types of tests mainly include the following: in-vitro, patch, intradermal, skin prick, and in vivo. As per drug classes, the divisions are immunotherapy, autoinjectable epinephrine, immunomodulators, decongestants, nasal anticholinergics, leukotriene inhibitors, mast cell stabilizers, corticosteroids, and antihistamines.

Geographically, the worldwide allergy diagnostics and therapeutics market is divided into Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa. Over the past couple of years, North America has been dominating the global market in terms of revenue earnings. The region may continue leading the industry over the forecast period. Growing acceptance of in vitro blood tests, awareness about allergy diagnostics, and rising cases of allergic respiratory anomalies are drivers of this region.

Europe is expected to register a high rate of growth because the region boasts of a mature pharmaceuticals industry. Surging demand for therapeutics is also a prominent regional driver. Other factors are rising cases allergic conditions and a rapidly expanding geriatric population. Asia Pacific may expand rapidly till 2022 owing to a rapidly developing medical infrastructure and surging demand for minimally invasive diagnostics solutions.

The global allergy diagnostics and therapeutics market is a highly fragmented one with a host of companies continuously striving towards larger market shares. Lincoln Diagnostics, Siemens Healthcare, Hitachi Chemical Diagnostics, Alcon Laboratories, and Hycor Biomedical are some of the prominent competitors operating in the global market.

In May 2016, Thermo Fisher Scientific licensed ProBioGen AG’s GlymaxX® technology for the development of allergy diagnostics. ProBioGen AG is a Germany based CDMO (contract development and manufacturing organization) & technology provider. Its key areas of focus are GMP production of biopharmaceuticals, process development, and cell lining engineering. The GlymaxX® technology yields antibodies with lower fucose content, is applicable to different types of species, needs no culture additives, and can even lead to enhanced productivity.

Browse Related Category Market Reports@

https://www.hexaresearch.com/research-category/clinical-diagnostics-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com/

Pharmaceuticals and Food Anti-Counterfeiting Technologies Market Research Report and Forecast to 2020 | Hexa Research

Proliferation of cheap but poor quality counterfeit products in the pharmaceutical and food sector and the resultant losses, are a growing concern, globally. Key anti-counterfeiting technologies include overt or visible feature enabling, covert feature enabling, forensic, and track/trace technologies. Counterfeiting not only leads to huge losses but also negatively affects brand image of industry operators. According to a recent study by Hexa Research, the global pharmaceuticals and food anti-counterfeiting market is set to reach more than $160 billion by 2020. US Food and Drug Administration (FDA), is implementing stringent anti-counterfeiting regulations and supporting development of anti-counterfeit devices.

Technological segmentation of the market includes authentication and tracking technologies. Tracking technologies can be split into RFID and barcodes. Barcodes offer advantages like traceability, accuracy and affordability. It was the leading technology in 2013. RFID will experience exponential growth with a CAGR of about 20% from the period 2013 to 2020. Authentication is split into inks and dyes, hologram, taggants, etc. Hologram accounted for the largest market share in 2013 and will grow at a rate of more than 15.9% from 2013 to 2020.

Browse Details of Report@

https://www.hexaresearch.com/research-report/pharmaceuticals-and-food-anti-counterfeiting-technologies-industry

Between pharmaceutical and food applications, pharmaceutical applications accounted for higher share of anti-counterfeiting products. Pharmaceutical sector places high value on quality and invests in superior technologies that prohibit patients from consuming low quality counterfeit products. Governmental regulations also play an important role in higher demand from pharmaceutical industry. However, food application is likely to witness fastest growth in the coming years, primarily due to rising awareness levels amongst market participants.

Backed by governmental interventions and advanced healthcare infrastructure, North America, with a market valuation of about $46 billion, was the largest regional consumer of pharmaceutical and food anti-counterfeiting products in 2012. Europe was second to North America with a market share of more than 16.8%. Hexa Research opines that the fastest growth of pharmaceuticals and food anti-counterfeiting market in future years is likely to come from emerging economies such as Asia Pacific countries and Latin American countries, among others. Large scale counterfeiting practices, rising income levels and healthcare infrastructure developments in emerging markets of India, China and Brazil will drive this growth. Key players of the global pharmaceuticals and food anti-counterfeiting industry are Data System International, Sun Chemical, Datamax, Intermec Technologies, Alien Technology, Inksure Technologies, Unibar Inc., etc.

Browse Related Category Market Reports @

https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com/

Follow us on Linkedin: https://www.linkedin.com/company/hexa-research

Contraceptives Market Research Report - Global Industry Analysis and Forecast to 2024 | Hexa Research

The global contraceptives market size will reach around USD 31 million by 2024, as reported by Hexa Research. Its demand should be driven by regulatory proposals on the prevention of unplanned pregnancies and favorable governmental framework. Furthermore, the market is estimated to be propelled by awareness regarding reproductive health & contraceptives.

Industry size accounted for nearly USD 20 million in 2015. The Contraceptives Market would expand at about 6.8% CAGR in the forecast period (2016 to 2024). Rising prevalence of veneral diseases (HIV, syphilis, etc) and demand for ‘population control’ positively affect the industry. While women adopting contraception across emerging regions have increased, more women not adopting the same have been registered globally.

Browse Details of Report@

https://www.hexaresearch.com/research-report/contraceptives-market

With rising women reaching reproductive age, national health ministries are engaged in widening health awareness & distribution channels. In spite of contraceptive innovations and related expenses per annum, the rate of unplanned pregnancies in the United States has remained the same in the past few years. The federal policy of the U.S. has taken steps to augment the availability of contraceptives & make ECs (Emergency Contraceptives) available OVCs (Over-The-Counters).

The availability of an extensive product line within the industry provides expansion prospects. The contraceptives market is fragmented by products, applications, and geographies. Vaginal implants, sponges, diaphragms, condoms, femdoms, subdermal implants, IUDs, and others are the products. In a research conducted lately, subdermal implants have been found to possess vast potential for family planning. IUDs accounted for one of the biggest shares in 2014 due to demand in Europe & Asia Pacific.

Gynecologists selecting IUDs for birth-control are expected to raise segment growth. Mirena, a hormonal IUD, employed broadly across North America could enhance the regional sales of IUDs. There are three kinds of contraceptive drugs. These are pills, injectables, and topical. Pills led the industry in 2014 in view of their large client-base and reproductive women’s unmet demands.

Applications comprise homes, clinics, hospitals, and others. Clinics occupied substantial shares and provide services across all genders & ages. Hospitals are known for offering permanent contraception. Homes produced the maximum sales. On the basis of regions, the contraceptives market is divided into North America, Europe, Asia Pacific, and rest of the world.

North America captured the largest shares in 2015. Its shares were attributed to high abortion rates & patient awareness. Europe observes huge penetration of subdermal implants and IUDs. Rest of the world will expand rapidly due to its vast unexplored prospects. An unmet contraceptive demand of approximately 215 million people globally is likely to propel this region. Asia Pacific impacts the worldwide Contraceptives market in reference to demographics & low awareness.

The Female Health Company, Church & Dwight, Cooper Surgical, and Actavis plc accounted for majority of the global revenues. Rivalry in the worldwide industry will stay relatively high till 2024. Industry manufacturers face continuous pressure to introduce technologically-innovative and novel products. The industry has been a witness to advancements in terms of self-administrative contraceptives. New product developments in response to the demand for innovative contraception are one of the basic strategies employed by players to occupy higher shares.

Browse Related Category Market Reports @

https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com/

Follow us on Linkedin: https://www.linkedin.com/company/hexa-research